New CMOs at Design, Mesoblast
Plus Loerop becomes CBO at Aclaris, updates from Clover, Kura, Fabric and more
Design Therapeutics Inc. (NASDAQ:DSGN) hired Jae Kim as CMO. Kim was CMO at Avidity Biosciences Inc. (NASDAQ:RNA) and VP, clinical development at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), where he played a key role in the development and approval of the small interfering RNA therapy Givlaari givosiran to treat acute hepatic porphyria. Kim also held roles of increasing responsibility at MyoKardia Inc. and Amgen Inc. (NASDAQ:AMGN). Design plans to begin its first clinical trial for Friedreich’s ataxia in 1H22.
Mesoblast Ltd. (NASDAQ:MESO; ASX:MSB), which is developing allogeneic cellular medicines for inflammatory disease, hired Eric Rose as CMO, replacing Fred Grossman. Rose served on the National Biodefense Scientific Board, which advises the U.S. Department of Health and Human Services; was chairman and CEO of Siga Technologies Inc. (NASDAQ:SIGA), where he oversaw development of TPOXX, the first antipoxviral drug approved in the U.S.; and has been a non-executive director at Mesoblast since 2013. ...